Two patients with intractable constipation and an atonic bladder due to a partial spinal cord lesion and sacral nerve lesion are described.
Introduction
Faecal stasis with colonic dilation and urinary incontinence is a distressing problem in patients with a spinal cord lesion and iatrogenic neurological damage after lower pelvic surgery (Glick et al., 1984) . Cholinergic agents have been used in an attempt to overcome the lack of para-sympathetic cholinergic stimu lation but they are disappointing because of their side effects. Recently, cis apride has been described as a non-cholinergic gastro-intestinal motor stimulant Reyntjes et al. (1984) , supposedly acting through increased release of acetyl choline in the intramural plexuses. Its prokinetic effects on gastro-intestinal motility have been demonstrated in patients with motility disorders of the upper gastro-intestinal tract (Jian, 1985; Smout et al., 1985) , however its effect on colonic dysfunction with faecal stasis caused by lesions of the spinal cord or iatrogenic damage of the sacral nerves, has not been described. Recently, we have succesfully used cisapride in 2 patients with constipation of neurological constipation. It was concluded that the constipation was due to the spinal cord lesion.
The patient was treated with cisapride, 4 x 10 mg daily. From the third day onwards a stool was passed spontaneously once a day. Two months later we tried to reduce the dose to 2 x 10 mg daily, but this resulted in a relapse of the constipation. After restoring the original dose, bowel movement occurred spontaneously again once a day. After 3 months, discontinuation of the therapy for 1 week resulted in a prompt relapse, whereafter the cisapride treatment was reinstated with an excellent result. Resolution of constipation has been maintained now for more than 40 months. Transient side-effects included headache, nausea and increased frequency of micturition. It was concluded that the constipation and the atonic bladder dysfunction were due to iatrogenic damage of (sacral) recto-colon enervation. The patient was treated with cisa pride 4 x 10 mg daily, and after 2 weeks the stool passed spontaneously once a day and the patient has regained the sensation of the urge to defecate.
Discussion
Cisapride is a gastro-intestinal prokinetic drug which has no anti-dopaminergic and no cholinergic effects. Its prokinetic effect on colon motility is not exactly understood but probably acts by stimulating directly the colonic smooth muscle and secondly by releasing acetylcholine at nerve endings in the myenteric plexus.
The propulsive effect of cisapride has been demonstrated in patients with chronic functional constipation (Muller-Lissner, 1986 ) and in patients with diabetic enteropathy (Rederer et ai., 1986). It therefore seemed justified to treat our patients with cisapride. Although the results of our study are promising we are fully aware of the restrictions imposed by the open nature of the study and by having treated only two patients so far. However a placebo effect seems unlikely, because the improvement has been sustained now for more than 40 months, and furthermore the reduction of the dose led to relapse of the consti pation.
Although cisapride did not result in normal bladder function, but increased contractability of the bladder, the ultimate effect resulted in more efficient bladder emptying with the absence of frequent bladder infection.
Our preliminary results justify further clinical trials of cisapride as a useful therapy of intractable constipation in patients with certain neural lesions.
